Literature DB >> 18209589

Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients.

Patrick Yachimski1, Daniel S Pratt.   

Abstract

Cholangiocarcinoma is a primary malignancy of biliary epithelium. Risk factors for cholangiocarcinoma include primary sclerosing cholangitis and other conditions that produce chronic inflammation of the biliary tree. The diagnosis of cholangiocarcinoma can be elusive; it is often not made until advanced disease is present and at a stage when a curative surgical resection is not feasible. Currently used diagnostic modalities include serum and bile tumor markers, radiologic and endoscopic imaging, and pathologic analysis. Surveillance strategies to increase the chance of early diagnosis should be strongly considered in individuals at high risk for cholangiocarcinoma. Patients with long-standing primary sclerosing cholangitis would be the ideal candidates for a screening program.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18209589     DOI: 10.1097/MCG.0b013e31806daf89

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  19 in total

1.  Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma.

Authors:  Megan E McNally; Amy Collins; Sylwia E Wojcik; James Liu; Jon C Henry; Jinmai Jiang; Thomas Schmittgen; Mark Bloomston
Journal:  HPB (Oxford)       Date:  2012-07-04       Impact factor: 3.647

2.  Deranged liver function tests in pregnancy: the importance of postnatal follow-up.

Authors:  Sophia Stone; Joanna C Girling
Journal:  Obstet Med       Date:  2009-03-01

3.  PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.

Authors:  Francesco Sabbatino; Vincenzo Villani; Jennifer H Yearley; Vikram Deshpande; Lei Cai; Ioannis T Konstantinidis; Christina Moon; Sjoerd Nota; Yangyang Wang; Ahmad Al-Sukaini; Andrew X Zhu; Lipika Goyal; David T Ting; Nabeel Bardeesy; Theodore S Hong; Carlos Fernandez-del Castillo; Kenneth K Tanabe; Keith D Lillemoe; Soldano Ferrone; Cristina R Ferrone
Journal:  Clin Cancer Res       Date:  2015-09-15       Impact factor: 12.531

Review 4.  Cholangiocarcinoma: has there been any progress?

Authors:  Judith Meza-Junco; Aldo J Montano-Loza; Mang Ma; Winnie Wong; Michael B Sawyer; Vincent G Bain
Journal:  Can J Gastroenterol       Date:  2010-01       Impact factor: 3.522

5.  New insights on cholangiocarcinoma.

Authors:  Manuela Gatto; Domenico Alvaro
Journal:  World J Gastrointest Oncol       Date:  2010-03-15

Review 6.  Hilar cholangiocarcinoma: pathology and tumor biology.

Authors:  Dong Kuang; Guo-Ping Wang
Journal:  Front Med China       Date:  2010-11-25

7.  Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity as possible biomarkers for patient prognosis.

Authors:  Munehiro Yoshitomi; Shigeru Yutani; Satoko Matsueda; Tetsuya Ioji; Nobukazu Komatsu; Shigeki Shichijo; Akira Yamada; Kyogo Itoh; Tetsuro Sasada; Hisafumi Kinoshita
Journal:  Exp Ther Med       Date:  2011-12-20       Impact factor: 2.447

Review 8.  Current status of immunotherapy for the treatment of biliary tract cancer.

Authors:  Ryuji Takahashi; Munehiro Yoshitomi; Shigeru Yutani; Takahisa Shirahama; Masanori Noguchi; Akira Yamada; Kyogo Itoh; Tetsuro Sasada
Journal:  Hum Vaccin Immunother       Date:  2013-02-01       Impact factor: 3.452

Review 9.  Primary sclerosing cholangitis.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

10.  Ultrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology.

Authors:  Chanjuan Shi; Arjun Chandrasekaran; Paul J Thuluvath; Collins Karikari; Pedram Argani; Michael Goggins; Anirban Maitra; James R Eshleman
Journal:  J Mol Diagn       Date:  2009-10-08       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.